

**Health Technology Appraisal: Psoriatic Arthritis – Etanercept,  
Infliximab & Adalimumab**

Comments from the Therapeutics and Guidelines Sub-Committee of the  
British Association of Dermatologists  
January 2010

This Health Technology Appraisal, concerning the use of biological agents in the treatment of psoriatic arthritis, was thought to be very comprehensive by members of the Therapeutics and Guidelines Sub-committee of the British Association of Dermatologists, and no specific points were raised regarding the technical content.

M.J.Tidman,  
Chair of BAD Therapeutics and Guidelines Sub-Committee.

24<sup>th</sup> January 2010